Results 91 to 100 of about 4,340 (195)

Plasma and cerebrospinal fluid pharmacokinetics of the histone deacetylase inhibitor, belinostat (PXD101), in non-human primates

, 2008
PURPOSE: Histone deacetylases (HDAC) are involved in the regulation of gene transcription. Aberrant HDAC activity has been associated with tumorigenesis, and, therefore, HDACs are potential targets for the treatment of cancers, including tumors of the ...
Warren, K.E., Tjornelund, J., Lichenstein, H.S., Dvinge, H., Sehested, M., McCully, C., Balis, F.M.   +6 more
core  

Belinostat decreases both male and female bladder weights in transgenic superficial bladder cancer mice

, 2011
Copyright information:Taken from "The histone deacetylase inhibitor belinostat (PXD101) suppresses bladder cancer cell growth in vitro and in vivo"http://www.translational-medicine.com/content/5/1/49Journal of Translational Medicine 2007;5():49-49 ...
Joanne Yoon (37162), Herman Yee (120), Xue-Ru Wu (37168), Michael T Buckley (37161), Leonard Liebes (119), Gulshan Ara (37164), Iman Osman (37169), Xiaozhong Qian (37165), Tung-Tien Sun (37167), Dean F Bajorin (37166), Luis Chiriboga (37163)   +10 more
core   +1 more source

Pharmacokinetic and pharmacodynamic properties of an oral formulation of the histone deacetylase inhibitor Belinostat (PXD101)

, 2010
The primary objective of this sub-study, undertaken as an extension to the previously reported phase-I study, was to explore the feasibility, tolerability and pharmacokinetics (PK) of belinostat when administered by the oral route.
de Bono, J. S., Buhl-Jensen, P., R. Brown, Plumb, J.A., Evans, T.R.J., Vidal, L., Knoblauch, P., J. S. de Bono, J. A. Plumb, P. Knoblauch, Molife, R., T. R. J. Evans, J. Tjørnelund, N. L. Steele, Steele, N.L., Brown, R., Tjørnelund, J., L. Vidal, P. Buhl-Jensen, R. Molife   +19 more
core   +1 more source

Publication Only

HemaSphere, Volume 10, Issue S1, June 2026.
wiley   +1 more source

LINFOMA DE LENNERT: RELATO DE CASO

Hematology, Transfusion and Cell Therapy
Introdução: O linfoma de Lennert ou linfoma linfoepitelióide é um subtipo raro de linfoma T. Os linfomas T periféricos são um grupo de doenças heterogêneas, com uma sobrevida global menor do que 32% em 5 anos. Relato de caso: Paciente masculino, 27 anos,
AP Gouvea, LF Negri, AC Fenili, FL Moreno, S Vidor, TB Soares, MEZ Capra, MO Ughini, LCG Trindade, DB Lamaison   +9 more
doaj   +1 more source

Phase II Study of Belinostat in Patients With Recurrent or Refractory Advanced Thymic Epithelial Tumors

, 2011
Purpose Thymic epithelial tumors are rare malignancies, and there is no standard treatment for patients with advanced disease in whom chemotherapy has failed. Antitumor activity of histone deacetylase (HDAC) inhibitors in this disease has been documented,
Arun Rajan, Jane Trepel, Patrick J. Loehrer, Ronan J. Kelly, Giuseppe Giaccone, Arlene Berman, Liang Cao, Eva Szabo, Min-Jung Lee, Ariel Lopez-Chavez, Igor Espinoza-Delgado, John Spittler   +11 more
core   +1 more source

Combined use of irinotecan with histone deacetylase inhibitor belinostat could cause severe toxicity by inhibiting SN-38 glucuronidation via UGT1A1

, 2017
© Lingzhi Wang et al. SN-38, the active metabolite of irinotecan, and histone deacetylase inhibitors (HDACis) such as belinostat, vorinostat and panobinostat, have all been shown to be deactivated by glucuronidation via UGTs.
Chan, C.E.L, Wong, F., Sethi, G, Lim, S., Wong, F.C, Chinnathambi, A, Yong, W., Lee, S.C, Lee, S., Wang, L., Goh, B., Chinnathambi, A., Lee, L., Wang, L, Lim, S.W, Alharbi, S., Chan, C., Yong, W.P, Ho, P., Sethi, Gautam, Alharbi, S.A, Wong, A.L.-A, Ho, P.C.-L, Goh, B.C, Soo, R, Wong, A., Soo, R., Lee, L.S.-U   +27 more
core   +1 more source

Complexation of histone deacetylase inhibitor belinostat to Cu(II) prevents premature metabolic inactivation in vitro and demonstrates potent anti-cancer activity in vitro and ex vivo in colon cancer

, 2023
Purpose: The histone deacetylase inhibitor (HDACi), belinostat, has had limited therapeutic impact in solid tumors, such as colon cancer, due to its poor metabolic stability. Here we evaluated a novel belinostat prodrug, copper-bis-belinostat (Cubisbel),
Anna Blümel (7898387), Ziga Ude (9256580), Wei Ding (690), Gregory Yochum (198567), Celine Marmion (7895267), Sara Terer (7899260), Flavia Genua (14508299), Ellen Finnegan (17308585), Lorraine Brennan (9439578), Xiaofei Yin (7899440), Sarinj Fattah (7899467), Tadhg McGivern (17462391), Jochen Prehn (7895672), Alexander Kel (14131), Sally-Ann Cryan (7896101), Grainne Kirwan (16912359), xinxin shao (13705099), Parvathi A Myer (12708923), Darran O'Connor (7895339), Sudipto Das (7896221)   +19 more
core   +1 more source

Phase II activity of belinostat (PXD-101), carboplatin, and paclitaxel in women with previously treated ovarian cancer

, 2012
BACKGROUND: Preclinical data show that belinostat (Bel) is synergistic with carboplatin and paclitaxel in ovarian cancer. To further evaluate the clinical activity of belinostat, carboplatin, and paclitaxel (BelCaP), a phase 1b/2 study was performed ...
Celano, Paul, Dizon, Don S, Knoblach, Poul, Lassen, Ulrik, Finkler, Neil J, Damstrup, Lars, Crowley, Elizabeth, Glasspool, Ros, Lichenstein, Henri S, Penson, Richard T   +9 more
core   +1 more source

CREB binding protein (CREBBP): Structure-based perspectives for the development of clinical inhibitors

Translational Oncology
Acetylation is an essential process in biological processes. In tissues, protein acetylation occurs mainly at lysine (K) residues. The balance between acetylation and deacetylation is under the control of two enzyme families, histone acetyltransferase ...
Rongxing Liu, Jiaxin Li, Qing Nian, Gao Tu, Zhenqiang Wang, Rong Zhang, Guobing Li   +6 more
doaj   +1 more source